Dantrolene Rescues Arrhythmogenic RYR2 Defect in a Patient-specific Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2011 Dec 17

PMID 22174035

Citations 179

Authors

Christian B Jung

Alessandra Moretti

Michael Mederos Y Schnitzler

Laura Iop

Ursula Storch

Milena Bellin

Tatjana Dorn

Sandra Ruppenthal

Sarah Pfeiffer

Alexander Goedel

Ralf J Dirschinger

Melchior Seyfarth

Jason T Lam

Daniel Sinnecker

Thomas Gudermann

Peter Lipp

Karl-Ludwig Laugwitz

Affiliations

Soon will be listed here.

Abstract

Coordinated release of calcium (Ca(2+) ) from the sarcoplasmic reticulum (SR) through cardiac ryanodine receptor (RYR2) channels is essential for cardiomyocyte function. In catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited disease characterized by stress-induced ventricular arrhythmias in young patients with structurally normal hearts, autosomal dominant mutations in RYR2 or recessive mutations in calsequestrin lead to aberrant diastolic Ca(2+) release from the SR causing arrhythmogenic delayed after depolarizations (DADs). Here, we report the generation of induced pluripotent stem cells (iPSCs) from a CPVT patient carrying a novel RYR2 S406L mutation. In patient iPSC-derived cardiomyocytes, catecholaminergic stress led to elevated diastolic Ca(2+) concentrations, a reduced SR Ca(2+) content and an increased susceptibility to DADs and arrhythmia as compared to control myocytes. This was due to increased frequency and duration of elementary Ca(2+) release events (Ca(2+) sparks). Dantrolene, a drug effective on malignant hyperthermia, restored normal Ca(2+) spark properties and rescued the arrhythmogenic phenotype. This suggests defective inter-domain interactions within the RYR2 channel as the pathomechanism of the S406L mutation. Our work provides a new in vitro model to study the pathogenesis of human cardiac arrhythmias and develop novel therapies for CPVT.

Citing Articles

An hiPSC-CM approach for electrophysiological phenotyping of a patient-specific case of short-coupled TdP.

van Ham W, Meijboom E, Ligtermoet M, Monshouwer-Kloots J, Te Riele A, Asselbergs F Stem Cell Res Ther. 2024; 15(1):470.

PMID: 39695883 PMC: 11656816. DOI: 10.1186/s13287-024-04074-8.

The Role of Human-Induced Pluripotent Stem Cells in Studying Cardiac Channelopathies.

Begovic M, Schneider L, Zhou X, Hamdani N, Akin I, El-Battrawy I Int J Mol Sci. 2024; 25(22).

PMID: 39596103 PMC: 11593457. DOI: 10.3390/ijms252212034.

Stem cell models of inherited arrhythmias.

Ryan T, Roberts J Nat Cardiovasc Res. 2024; 3(4):420-430.

PMID: 39196215 DOI: 10.1038/s44161-024-00451-x.

Using induced pluripotent stem cells for drug discovery in arrhythmias.

Teles D, Fine B Expert Opin Drug Discov. 2024; 19(7):827-840.

PMID: 38825838 PMC: 11227103. DOI: 10.1080/17460441.2024.2360420.

Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.

Aggarwal A, Stolear A, Alam M, Vardhan S, Dulgher M, Jang S J Clin Med. 2024; 13(6).

PMID: 38542006 PMC: 10971616. DOI: 10.3390/jcm13061781.

References

Thomas N, Maxwell C, Mukherjee S, Williams A . Ryanodine receptor mutations in arrhythmia: The continuing mystery of channel dysfunction. FEBS Lett. 2010; 584(10):2153-60. DOI: 10.1016/j.febslet.2010.01.057. View

Liu N, Rizzi N, Boveri L, Priori S . Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol. 2008; 46(2):149-59. DOI: 10.1016/j.yjmcc.2008.10.012. View

Kaye D, Hoshijima M, Chien K . Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med. 2008; 59:13-28. DOI: 10.1146/annurev.med.59.052407.103237. View

George C, Higgs G, Lai F . Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003; 93(6):531-40. DOI: 10.1161/01.RES.0000091335.07574.86. View

Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M . Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009; 53(21):1993-2005. PMC: 2764410. DOI: 10.1016/j.jacc.2009.01.065. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Krause T, Gerbershagen M, Fiege M, Weisshorn R, Wappler F . Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004; 59(4):364-73. DOI: 10.1111/j.1365-2044.2004.03658.x. View

Lanner J, Georgiou D, Joshi A, Hamilton S . Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010; 2(11):a003996. PMC: 2964179. DOI: 10.1101/cshperspect.a003996. View

Kobayashi S, Yano M, Uchinoumi H, Suetomi T, Susa T, Ono M . Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J. 2010; 74(12):2579-84. DOI: 10.1253/circj.cj-10-0680. View

10.

Paul-Pletzer K, Yamamoto T, Bhat M, Ma J, Ikemoto N, Jimenez L . Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002; 277(38):34918-23. DOI: 10.1074/jbc.M205487200. View

11.

Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez L, Morimoto H, Williams P . Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J. 2005; 387(Pt 3):905-9. PMC: 1135024. DOI: 10.1042/BJ20041336. View

12.

Kaufman E . Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm. 2009; 6(8 Suppl):S51-5. DOI: 10.1016/j.hrthm.2009.02.009. View

13.

Gupta M, Illich D, Gaarz A, Matzkies M, Nguemo F, Pfannkuche K . Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol. 2010; 10:98. PMC: 2946283. DOI: 10.1186/1471-213X-10-98. View

14.

Jiang D, Wang R, Xiao B, Kong H, Hunt D, Choi P . Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005; 97(11):1173-81. DOI: 10.1161/01.RES.0000192146.85173.4b. View

15.

Carvajal-Vergara X, Sevilla A, DSouza S, Ang Y, Schaniel C, Lee D . Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010; 465(7299):808-12. PMC: 2885001. DOI: 10.1038/nature09005. View

16.

Zhu H, Lensch M, Cahan P, Daley G . Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet. 2011; 12(4):266-75. DOI: 10.1038/nrg2951. View

17.

Moretti A, Bellin M, Welling A, Jung C, Lam J, Bott-Flugel L . Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010; 363(15):1397-409. DOI: 10.1056/NEJMoa0908679. View

18.

Wehrens X, Lehnart S, Huang F, Vest J, Reiken S, Mohler P . FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003; 113(7):829-40. DOI: 10.1016/s0092-8674(03)00434-3. View

19.

Lehnart S, Mongillo M, Bellinger A, Lindegger N, Chen B, Hsueh W . Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest. 2008; 118(6):2230-45. PMC: 2381750. DOI: 10.1172/JCI35346. View

20.

Gyorke S, Terentyev D . Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res. 2007; 77(2):245-55. DOI: 10.1093/cvr/cvm038. View